S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:IMAB

I-Mab - IMAB Stock Forecast, Price & News

$7.97
-0.73 (-8.39%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$7.90
$8.69
50-Day Range
$7.97
$12.35
52-Week Range
$6.52
$80.88
Volume
299,662 shs
Average Volume
1.03 million shs
Market Capitalization
$658.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$68.25

I-Mab MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
756.3% Upside
$68.25 Price Target
Short Interest
Healthy
4.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.10mentions of I-Mab in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.72) to ($3.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

523rd out of 1,098 stocks

Pharmaceutical Preparations Industry

247th out of 536 stocks

IMAB stock logo

About I-Mab (NASDAQ:IMAB) Stock

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on IMAB shares. Needham & Company LLC cut their price target on I-Mab from $85.00 to $72.00 and set a "buy" rating for the company in a research note on Tuesday, May 31st. Piper Sandler cut their price target on I-Mab from $80.00 to $35.00 in a research note on Friday, May 27th. Finally, HC Wainwright cut their price target on I-Mab from $80.00 to $70.00 and set a "buy" rating for the company in a research note on Tuesday, May 31st.

I-Mab Price Performance

I-Mab stock opened at $8.70 on Tuesday. I-Mab has a 52 week low of $6.52 and a 52 week high of $80.88. The company's 50 day moving average price is $10.19 and its two-hundred day moving average price is $15.19.

Receive IMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for I-Mab and its competitors with MarketBeat's FREE daily newsletter.

IMAB Stock News Headlines

I-Mab (NASDAQ:IMAB) Shares Down 5.5%
I-Mab (NASDAQ:IMAB) Shares Up 7.2%
I-Mab (NASDAQ:IMAB) Trading Down 4.4%
I-Mab to Host 2022 R&D Day
See More Headlines
Receive IMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for I-Mab and its competitors with MarketBeat's FREE daily newsletter.

IMAB Company Calendar

Today
8/09/2022
Next Earnings (Estimated)
8/29/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMAB
Fax
N/A
Employees
228
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$68.25
High Stock Price Forecast
$96.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+756.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$13.81 million
Book Value
$8.95 per share

Miscellaneous

Free Float
N/A
Market Cap
$658.69 million
Optionable
Not Optionable
Beta
0.59

Key Executives

  • Dr. Jingwu Zhang Zang M.D. (Age 66)
    Ph.D., Founder, Chairman & Acting CEO
  • Dr. Zheru Zhang Ph.D. (Age 59)
    Pres & Director
  • Dr. Andrew X. Zhu M.D. (Age 62)
    Ph.D., Member of Scientific Advisory Board, Pres & Director
  • Dr. Jerry Wang
    Co-Founder & Chief Scientific Officer
  • Mr. John Long (Age 50)
    CFO & Director
  • Mr. Richard L. Yeh (Age 53)
    COO & Director
  • Mr. Tianyi Zhang
    VP of Investor Relations
  • Mr. Cheng Li (Age 38)
    Chief Legal Officer
  • Ms. Gigi Qi Feng (Age 41)
    Chief Communications Officer
  • Dr. Weiming Tang Ph.D. (Age 56)
    Exec. VP of Global Bus. Devel. & Chief Bus. Officer













IMAB Stock - Frequently Asked Questions

Should I buy or sell I-Mab stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for I-Mab in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMAB shares.
View IMAB analyst ratings
or view top-rated stocks.

What is I-Mab's stock price forecast for 2022?

3 Wall Street research analysts have issued 1-year target prices for I-Mab's stock. Their IMAB share price forecasts range from $35.00 to $96.00. On average, they predict the company's stock price to reach $68.25 in the next twelve months. This suggests a possible upside of 744.7% from the stock's current price.
View analysts price targets for IMAB
or view top-rated stocks among Wall Street analysts.

How has I-Mab's stock performed in 2022?

I-Mab's stock was trading at $47.39 on January 1st, 2022. Since then, IMAB shares have decreased by 82.9% and is now trading at $8.08.
View the best growth stocks for 2022 here
.

When is I-Mab's next earnings date?

I-Mab is scheduled to release its next quarterly earnings announcement on Monday, August 29th 2022.
View our IMAB earnings forecast
.

What other stocks do shareholders of I-Mab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other I-Mab investors own include Inovio Pharmaceuticals (INO), Moderna (MRNA), ServiceNow (NOW), Novavax (NVAX), Gilead Sciences (GILD), Cisco Systems (CSCO), Enterprise Products Partners (EPD), G1 Therapeutics (GTHX), Intel (INTC) and Johnson & Johnson (JNJ).

When did I-Mab IPO?

(IMAB) raised $100 million in an initial public offering on Thursday, January 16th 2020. The company issued 7,400,000 shares at a price of $12.00-$15.00 per share. Jefferies and CICC acted as the underwriters for the IPO and China Renaissance and Huatai Securities (USA) were co-managers.

What is I-Mab's stock symbol?

I-Mab trades on the NASDAQ under the ticker symbol "IMAB."

Who are I-Mab's major shareholders?

I-Mab's stock is owned by many different retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.56%) and Northwestern Mutual Wealth Management Co. (0.00%).

How do I buy shares of I-Mab?

Shares of IMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is I-Mab's stock price today?

One share of IMAB stock can currently be purchased for approximately $8.08.

How much money does I-Mab make?

I-Mab (NASDAQ:IMAB) has a market capitalization of $667.81 million and generates $13.81 million in revenue each year.

How many employees does I-Mab have?

I-Mab employs 228 workers across the globe.

How can I contact I-Mab?

I-Mab's mailing address is SUITE 802 WEST TOWER OMNLVISION 88 SHANGKE ROAD PUDONG DISTRICT, SHANGHAI F4, 201210. The official website for the company is www.i-mabbiopharma.com. The company can be reached via phone at 86-21-6057-8000 or via email at ir@i-mabbiopharma.com.

This page (NASDAQ:IMAB) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.